Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis' Entresto Blockbuster Status On Track After CHMP Backing

This article was originally published in Scrip

Executive Summary

Novartis' heart failure pill Entresto is already predicted to reach blockbuster status on the strength of its July approval in the US and now formal recommendation by CHMP in Europe for patients with reduced ejection fraction – representing some 50% of chronic heart failure patients - but those prospects could soar if an ongoing Phase III study presents the opportunity to eventually move the agent into the other half of chronic heart failure patients, those having preserved ejection fraction.



Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts